BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

This morning, the White House released its initiative to lower healthcare costs that includes the ability for Medicare to negotiate prices for prescription drugs.

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23rd at 5:00 PM ET.

Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and six-months ended June 30, 2021.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright Ophthalmology Virtual Conference

MediciNova, Inc., a biopharmaceutical company developing small-molecule therapeutics, reported financial results for the second quarter ended June 30, 2021 and provided a business update including results of a safety review from the ongoing Phase 2 trial of MN-166 in glioblastoma and results from the completed Phase 2 trial of MN-001 in idiopathic pulmonary fibrosis.

The U.S. Food and Drug Administration amended the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2021 and provided an update on recent developments.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.